Literature DB >> 20232181

Cryoimmunologic antitumor effects enhanced by dendritic cells in osteosarcoma.

Masanori Kawano1, Hideji Nishida, Yasunari Nakamoto, Hiroshi Tsumura, Hiroyuki Tsuchiya.   

Abstract

BACKGROUND: We previously reported a limb-salvage technique by treating tumor-bearing bone with liquid nitrogen. We also reported systemic antitumor immunity was enhanced by cryotreatment in a murine osteosarcoma (LM8) model. We therefore combined the cryotreatment of tumor with dendritic cells to promote tumor-specific immune responses. QUESTIONS/PURPOSES: We determined whether our technique could enhance systemic immune response and inhibit metastatic tumor growth in a murine osteosarcoma model.
MATERIALS AND METHODS: To evaluate activation of the immune response, we prepared six groups of C3H mice (80 mice total): (1) excision only, (2) dendritic cells without reimplantation of the cryotreated primary tumor, (3) reimplantation of the cryotreated primary tumor alone, (4) dendritic cells combined with reimplantation of the cryotreated primary tumor, (5) dendritic cells exposed to cryotreated tumor lysates without reimplantation of the cryotreated primary tumor, and (6) dendritic cells exposed to cryotreated tumor lysates with reimplantation of the cryotreated primary tumor. We then compared and verified the activation state of each group's antitumor immunity.
RESULTS: Mice that received dendritic cells exposed to cryotreated tumor lysates with reimplantation of the cryotreated primary tumor group had high serum interferon gamma, reduced pulmonary metastases, and increased numbers of CD8(+) T lymphocytes in the metastatic areas.
CONCLUSIONS: Combining tumor cryotreatment with dendritic cells enhanced systemic immune responses and inhibited metastatic tumor growth. CLINICAL RELEVANCE: We suggest immunotherapy could be developed further to improve the treatment of osteosarcoma.

Entities:  

Mesh:

Year:  2010        PMID: 20232181      PMCID: PMC2853649          DOI: 10.1007/s11999-010-1302-z

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  50 in total

1.  Adoptive immunotherapy in primary osteosarcoma. An interim report.

Authors:  J R Neff; W F Enneking
Journal:  J Bone Joint Surg Am       Date:  1975-03       Impact factor: 5.284

2.  Editorial: New therapies for osteogenic sarcoma.

Authors:  C J Campbell; J Cohen; W F Enneking
Journal:  J Bone Joint Surg Am       Date:  1975-03       Impact factor: 5.284

3.  Caffeine-assisted chemotherapy and minimized tumor excision for nonmetastatic osteosarcoma.

Authors:  H Tsuchiya; K Tomita; Y Mori; N Asada; T Morinaga; S Kitano; N Yamamoto
Journal:  Anticancer Res       Date:  1998 Jan-Feb       Impact factor: 2.480

4.  Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.

Authors:  Paul A Meyers; Cindy L Schwartz; Mark Krailo; Eugenie S Kleinerman; Donna Betcher; Mark L Bernstein; Ernest Conrad; William Ferguson; Mark Gebhardt; Allen M Goorin; Michael B Harris; John Healey; Andrew Huvos; Michael Link; Joseph Montebello; Helen Nadel; Michael Nieder; Judith Sato; Gene Siegal; Michael Weiner; Robert Wells; Lester Wold; Richard Womer; Holcombe Grier
Journal:  J Clin Oncol       Date:  2005-03-20       Impact factor: 44.544

5.  Neoadjuvant chemotherapy and local radiotherapy for high-grade osteosarcoma of the extremities.

Authors:  Gennady N Machak; Sergey I Tkachev; Yuriy N Solovyev; Pavel A Sinyukov; Stanislav M Ivanov; Natalya V Kochergina; Alexey D Ryjkov; Valery V Tepliakov; Benjamin Y Bokhian; Valeria V Glebovskaya
Journal:  Mayo Clin Proc       Date:  2003-02       Impact factor: 7.616

6.  A unique mucin immunoenhancing peptide with antitumor properties.

Authors:  Lynn M Herbert; Joseph F Grosso; Mantley Dorsey; Tihui Fu; Iafa Keydar; Mabel A Cejas; Daniel H Wreschner; Nechama Smorodinski; Diana M Lopez
Journal:  Cancer Res       Date:  2004-11-01       Impact factor: 12.701

7.  [Autoclaved tumoral autografts. Apropos of 12 cases, 6 of which highly malignant].

Authors:  J Duparc; P Massin; L Bocquet; E Benfrech; R Cavagna
Journal:  Rev Chir Orthop Reparatrice Appar Mot       Date:  1993

Review 8.  Potential role of NK cells in the induction of immune responses: implications for NK cell-based immunotherapy for cancers and viral infections.

Authors:  Hiroshi Terunuma; Xuewen Deng; Zahidunnabi Dewan; Shigeyoshi Fujimoto; Naoki Yamamoto
Journal:  Int Rev Immunol       Date:  2008       Impact factor: 5.311

9.  Immunotherapy with irradiated tumour cells and BCG in experimental osteosarcoma.

Authors:  S E Larsson; R Lorentzon; L Boquist
Journal:  Acta Orthop Scand       Date:  1981-10

10.  Re-implantation of tumour tissue treated by cryotreatment with liquid nitrogen induces anti-tumour activity against murine osteosarcoma.

Authors:  H Nishida; H Tsuchiya; K Tomita
Journal:  J Bone Joint Surg Br       Date:  2008-09
View more
  14 in total

1.  Freezing Nitrogen Ethanol Composite May be a Viable Approach for Cryotherapy of Human Giant Cell Tumor of Bone.

Authors:  Po-Kuei Wu; Cheng-Fong Chen; Jir-You Wang; Paul Chih-Hsueh Chen; Ming-Chau Chang; Shih-Chieh Hung; Wei-Ming Chen
Journal:  Clin Orthop Relat Res       Date:  2017-02-14       Impact factor: 4.176

Review 2.  Cryoimmunology for malignant bone and soft-tissue tumors.

Authors:  Hideji Nishida; Norio Yamamoto; Yoshikazu Tanzawa; Hiroyuki Tsuchiya
Journal:  Int J Clin Oncol       Date:  2011-03-12       Impact factor: 3.402

3.  Dendritic cells combined with doxorubicin induces immunogenic cell death and exhibits antitumor effects for osteosarcoma.

Authors:  Masanori Kawano; Kazuhiro Tanaka; Ichiro Itonaga; Tatsuya Iwasaki; Masashi Miyazaki; Shinichi Ikeda; Hiroshi Tsumura
Journal:  Oncol Lett       Date:  2016-02-02       Impact factor: 2.967

4.  Anti-TGF-β antibody combined with dendritic cells produce antitumor effects in osteosarcoma.

Authors:  Masanori Kawano; Ichiro Itonaga; Tatsuya Iwasaki; Hiroyuki Tsuchiya; Hiroshi Tsumura
Journal:  Clin Orthop Relat Res       Date:  2012-03-14       Impact factor: 4.176

5.  Pasteurization of bone for tumour eradication prior to reimplantation - an in vitro & pre-clinical efficacy study.

Authors:  Jyoti Kode; Prasad Taur; Ashish Gulia; Nirmala Jambhekar; Manish Agarwal; Ajay Puri
Journal:  Indian J Med Res       Date:  2014-04       Impact factor: 2.375

Review 6.  Curcumin in Osteosarcoma Therapy: Combining With Immunotherapy, Chemotherapeutics, Bone Tissue Engineering Materials and Potential Synergism With Photodynamic Therapy.

Authors:  Chunfeng Xu; Mingjie Wang; Wei Guo; Wei Sun; Yuelian Liu
Journal:  Front Oncol       Date:  2021-05-20       Impact factor: 6.244

7.  Light-Responsive Micelles Loaded With Doxorubicin for Osteosarcoma Suppression.

Authors:  Jiayi Chen; Chenhong Qian; Peng Ren; Han Yu; Xiangjia Kong; Chenglong Huang; Huanhuan Luo; Gang Chen
Journal:  Front Pharmacol       Date:  2021-06-18       Impact factor: 5.810

8.  TNF-α and tumor lysate promote the maturation of dendritic cells for immunotherapy for advanced malignant bone and soft tissue tumors.

Authors:  Shinji Miwa; Hideji Nishida; Yoshikazu Tanzawa; Munetomo Takata; Akihiko Takeuchi; Norio Yamamoto; Toshiharu Shirai; Katsuhiro Hayashi; Hiroaki Kimura; Kentaro Igarashi; Eishiro Mizukoshi; Yasunari Nakamoto; Shuichi Kaneko; Hiroyuki Tsuchiya
Journal:  PLoS One       Date:  2012-12-21       Impact factor: 3.240

9.  The Application of Cytidyl Guanosyl Oligodeoxynucleotide Can Affect the Antitumor Immune Response Induced by a Combined Protocol of Cryoablation and Dendritic Cells in Lewis Lung Cancer Model.

Authors:  Mi Zhang; Tianquan Yin; Yuan Lu; Huasong Feng
Journal:  Med Sci Monit       Date:  2016-04-19

10.  Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma.

Authors:  Pratistha Koirala; Michael E Roth; Jonathan Gill; Sajida Piperdi; Jordan M Chinai; David S Geller; Bang H Hoang; Amy Park; Michael A Fremed; Xingxing Zang; Richard Gorlick
Journal:  Sci Rep       Date:  2016-07-26       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.